Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb's BMS-986012?
BMS-986012 is a monoclonal antibody commercialized by Bristol-Myers Squibb, with a leading Phase II program in Small-Cell Lung Cancer. According...
BMS-986012 by Bristol-Myers Squibb for Small-Cell Lung Cancer: Likelihood of Approval
BMS-986012 is under clinical development by Bristol-Myers Squibb and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb's BMS-986012?
BMS-986012 is a monoclonal antibody commercialized by Bristol-Myers Squibb, with a leading Phase II program in Small-Cell Lung Cancer. According...